Edition:
United States

People: AfroCentric Investment Corporation Ltd (ACTJ.J)

ACTJ.J on Johannesburg Stock Exchange

610.00ZAc
23 Jun 2017
Change (% chg)

10.00 (+1.67%)
Prev Close
600.00
Open
609.00
Day's High
615.00
Day's Low
609.00
Volume
89,213
Avg. Vol
123,714
52-wk High
695.00
52-wk Low
475.00

Coughlin, Christopher 

Mr. Christopher J. Coughlin is Lead Independent Director of Allergan Plc. He joined the Board of Directors in July 2014. He previously served as a member of the Board of Directors of Forest beginning 2011. Mr. Coughlin is currently a Senior Advisor to McKinsey & Co., a role he has had since 2012. He was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco until September 2012. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004, as Chief Financial Officer from August 2003 to June 2004 and as a director from July 2003 to July 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996 he held various positions, including Chief Financial Officer, at Sterling Drug. Mr. Coughlin is currently serving as the Chairman of the Board of Dun & Bradstreet, where he is a former member of the Audit Committee, chairs the Nominating and Governance Committee, and is a member of the Compensation and Benefits Committee. He also serves on the Board of Directors of Alexion Pharmaceuticals where he is Chair of the Audit Committee and a member of the Pharmaceutical Compliance and Quality Committee. He is also on the Board of Directors of Hologic, Inc., where he sits on the Audit and Finance Committee. In addition, Mr. Coughlin previously served on the Boards of Directors of Covidien, Dipexium, the Interpublic Group of Companies, Monsanto Company and Perrigo Company. The Board of Directors concluded that Mr. Coughlin’s depth of experience in executive leadership roles within complex corporate org

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD 249,700
Long-Term Incentive Plans, USD --
All Other, USD 408,340
Fiscal Year Total, USD 658,040

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --